Health state utility values in locally advanced and metastatic breast cancer by treatment line : a systematic review
INTRODUCTION: For patients with late-stage (metastatic) breast cancer, the impact of treatment on health-related quality of life is a key factor in decision-making. A systematic review was conducted to identify health state utility values (HSUVs) for late-stage breast cancer, derived using methods preferred by health technology assessment (HTA) agencies, by treatment line. The aim was to generate a list of HSUVs, that could help to justify the values used to populate cost-utility models. Areas covered: Ten electronic databases, international congress websites and online HSUV databases were searched (January 1995-May 2014) for HSUVs for adults with late-stage breast cancer that had been derived from methods favoured by HTA agencies. Publications were included only if they reported studies that originated HSUVs. Expert commentary: Large numbers of HSUVs are available for late-stage breast cancer in the published literature. Contrary to expectations, the HSUVs reported in the literature vary greatly for some health states. As a result, the choice of HSUV can have considerable implications for the outcomes of economic evaluations. Standardization of HSUV methodology is expected to reduce variability; however, further research is recommended for assessing the sensitivity of generic preference-based measures in late-stage (metastatic) breast cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Expert review of pharmacoeconomics & outcomes research - 16(2016), 5 vom: 03. Okt., Seite 549-559 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Paracha, Noman [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 22.03.2017 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM263877078 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM263877078 | ||
| 003 | DE-627 | ||
| 005 | 20231224204845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0879.xml |
| 035 | |a (DE-627)NLM263877078 | ||
| 035 | |a (NLM)27574879 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Paracha, Noman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Health state utility values in locally advanced and metastatic breast cancer by treatment line |b a systematic review |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2017 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: For patients with late-stage (metastatic) breast cancer, the impact of treatment on health-related quality of life is a key factor in decision-making. A systematic review was conducted to identify health state utility values (HSUVs) for late-stage breast cancer, derived using methods preferred by health technology assessment (HTA) agencies, by treatment line. The aim was to generate a list of HSUVs, that could help to justify the values used to populate cost-utility models. Areas covered: Ten electronic databases, international congress websites and online HSUV databases were searched (January 1995-May 2014) for HSUVs for adults with late-stage breast cancer that had been derived from methods favoured by HTA agencies. Publications were included only if they reported studies that originated HSUVs. Expert commentary: Large numbers of HSUVs are available for late-stage breast cancer in the published literature. Contrary to expectations, the HSUVs reported in the literature vary greatly for some health states. As a result, the choice of HSUV can have considerable implications for the outcomes of economic evaluations. Standardization of HSUV methodology is expected to reduce variability; however, further research is recommended for assessing the sensitivity of generic preference-based measures in late-stage (metastatic) breast cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Advanced breast cancer | |
| 650 | 4 | |a cost–utility analysis | |
| 650 | 4 | |a health state utility | |
| 650 | 4 | |a health status | |
| 650 | 4 | |a metastatic breast cancer | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a quality of life index | |
| 650 | 4 | |a quality-adjusted life-year | |
| 650 | 4 | |a systematic review | |
| 650 | 4 | |a treatment line | |
| 700 | 1 | |a Thuresson, Per-Olof |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Santiago G |e verfasserin |4 aut | |
| 700 | 1 | |a MacGilchrist, Katherine S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of pharmacoeconomics & outcomes research |d 2001 |g 16(2016), 5 vom: 03. Okt., Seite 549-559 |w (DE-627)NLM187860815 |x 1744-8379 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2016 |g number:5 |g day:03 |g month:10 |g pages:549-559 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2016 |e 5 |b 03 |c 10 |h 549-559 | ||